CN113646442B - 新型dna适配体及其用途 - Google Patents

新型dna适配体及其用途 Download PDF

Info

Publication number
CN113646442B
CN113646442B CN201980092801.6A CN201980092801A CN113646442B CN 113646442 B CN113646442 B CN 113646442B CN 201980092801 A CN201980092801 A CN 201980092801A CN 113646442 B CN113646442 B CN 113646442B
Authority
CN
China
Prior art keywords
aptamer
cancer
dna
aptamers
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980092801.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN113646442A (zh
Inventor
金润姬
许钧
崔先一
金仁厚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Biology A Co ltd
National Cancer Center Korea
Original Assignee
Nippon Biology A Co ltd
National Cancer Center Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Biology A Co ltd, National Cancer Center Korea filed Critical Nippon Biology A Co ltd
Publication of CN113646442A publication Critical patent/CN113646442A/zh
Application granted granted Critical
Publication of CN113646442B publication Critical patent/CN113646442B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/13—Applications; Uses in screening processes in a process of directed evolution, e.g. SELEX, acquiring a new function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/205—Aptamer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201980092801.6A 2018-12-21 2019-08-08 新型dna适配体及其用途 Active CN113646442B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20180167948 2018-12-21
KR10-2018-0167948 2018-12-21
PCT/KR2019/009956 WO2020130269A1 (ko) 2018-12-21 2019-08-08 신규한 dna 앱타머 및 이의 용도

Publications (2)

Publication Number Publication Date
CN113646442A CN113646442A (zh) 2021-11-12
CN113646442B true CN113646442B (zh) 2024-12-03

Family

ID=71100532

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980092801.6A Active CN113646442B (zh) 2018-12-21 2019-08-08 新型dna适配体及其用途

Country Status (6)

Country Link
US (1) US12398395B2 (https=)
EP (1) EP3901287A4 (https=)
JP (1) JP7391971B2 (https=)
KR (1) KR102324242B1 (https=)
CN (1) CN113646442B (https=)
WO (2) WO2020130225A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020130225A1 (ko) * 2018-12-21 2020-06-25 국립암센터 췌장암 특이적으로 결합하는 dna 앱타머 및 이의 용도
KR102506295B1 (ko) 2020-08-28 2023-03-08 국립암센터 디그옥시제닌에 대한 인간화 항체 및 이의 용도
KR102506288B1 (ko) * 2020-09-07 2023-03-06 국립암센터 디그옥시제닌에 대한 항체를 포함하는 복합체, 및 이들의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020130225A1 (ko) * 2018-12-21 2020-06-25 국립암센터 췌장암 특이적으로 결합하는 dna 앱타머 및 이의 용도
KR20220032276A (ko) * 2020-09-07 2022-03-15 국립암센터 디그옥시제닌에 대한 항체를 포함하는 복합체, 및 이들의 용도
CN116157419A (zh) * 2020-08-28 2023-05-23 国立癌症中心 抗地高辛配基人源化抗体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US8563711B2 (en) * 2009-06-01 2013-10-22 Sungkyunkwan University Foundation For Corporate Collaboration Nucleic acid aptamer capable of binding specifically to pancreatic cancer cells or tissues and use thereof
KR101250557B1 (ko) * 2011-05-18 2013-04-03 국립암센터 Ｐａｕｆ 특이적 앱타머 및 이를 포함하는 췌장암 치료용 조성물
KR101699105B1 (ko) * 2012-04-02 2017-01-23 성균관대학교산학협력단 Ａｌｐｐｌ２ 단백질을 이용한 췌장암 진단 방법
KR101568400B1 (ko) * 2012-08-09 2015-11-12 연세대학교 산학협력단 암 줄기세포에 특이적으로 결합하는 핵산 앱타머 및 이의 용도
KR101458947B1 (ko) * 2013-03-05 2014-11-12 국립암센터 인터루킨-８ 앱타머 및 이의 용도
AU2016346269A1 (en) * 2015-10-30 2018-05-24 Tagcyx Biotechnologies DNA aptamer binding to cancer cell

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020130225A1 (ko) * 2018-12-21 2020-06-25 국립암센터 췌장암 특이적으로 결합하는 dna 앱타머 및 이의 용도
CN116157419A (zh) * 2020-08-28 2023-05-23 国立癌症中心 抗地高辛配基人源化抗体及其用途
KR20220032276A (ko) * 2020-09-07 2022-03-15 국립암센터 디그옥시제닌에 대한 항체를 포함하는 복합체, 및 이들의 용도

Also Published As

Publication number Publication date
US20220090081A1 (en) 2022-03-24
WO2020130269A1 (ko) 2020-06-25
US12398395B2 (en) 2025-08-26
JP2022516054A (ja) 2022-02-24
CN113646442A (zh) 2021-11-12
EP3901287A4 (en) 2022-10-26
KR20200078303A (ko) 2020-07-01
WO2020130225A1 (ko) 2020-06-25
KR102324242B1 (ko) 2021-11-11
JP7391971B2 (ja) 2023-12-05
EP3901287A1 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
JP5603933B2 (ja) 膵臓癌細胞または組織に特異的に結合できる核酸アプタマー及びその用途
CN113646442B (zh) 新型dna适配体及其用途
CN107001417A (zh) 靶向肽及其使用方法
CN113727602B (zh) 抗nme抗体及治疗癌症或癌症转移的方法
Bouvain et al. Non-invasive mapping of systemic neutrophil dynamics upon cardiovascular injury
Civit et al. Targeting hormone refractory prostate cancer by in vivo selected DNA libraries in an orthotopic xenograft mouse model
EP3149167B1 (en) Aptamer targeting mage-a3 peptide and uses thereof
CN104411825B (zh) 骨膜蛋白适配体及包含其的抗癌组合物
CN101632833A (zh) 一种前列腺癌相关的基因及其用途
JP6152550B2 (ja) 大腸癌細胞選択的膜透過性ペプチドおよびその利用
EP3914715A1 (en) Aptamer and use of the aptamer in the diagnosis and treatment of cancer
JP2024054164A (ja) グリピカン－３特異的変形アプタマー及びその用途
US20230285589A1 (en) Liposome complex for cancer treatment, comprising novel cd47 binder and polynucleotide
Lin et al. A self‐assembling LYTAC mediates CTGF degradation and remodels inflammatory tumor microenvironment for triple‐negative breast cancer therapy
CN108350459B (zh) 结合癌细胞的dna适配体
CN112779261B (zh) 结合人b7-h4蛋白的适配体及其应用和应用其的检测方法
CN114207132B (zh) 新型dna适体及其用途
US20230322893A1 (en) Cd47 binder and liposome complex for cancer treatment
US20230293571A1 (en) Polynucleotide for cancer treatment, encoding 5'-nucleotidase modified protein
JP2025518079A (ja) 腫瘍ナビゲートペプチドによる、ｍｉＲＮＡベースの癌の治療方法
Bell Targeting Cell Surface GRP78 Receptor with Hybrid Peptides as Drug Carriers
KR20240142290A (ko) Lag-3에 결합하는 펩타이드 및 이의 용도
Mayer targeting hormone refractory prostate cancer by in vivoselected DNA libraries in an orthotopic xenograft mouse model

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant